
Tyra Biosciences (TYRA) Stock Forecast & Price Target
Tyra Biosciences (TYRA) Analyst Ratings
Bulls say
Tyra Biosciences Inc. holds a strong positive outlook due to its innovative precision medicine platform, SNAP, which enables swift and accurate drug design, positioning the company favorably within the biotechnology sector. The potential of TYRA-300, particularly in its ability to achieve meaningful improvements in patient outcomes such as height velocity and overall tolerability, presents a significant advancement over existing therapies. Moreover, the first oral FGFR3 therapy is anticipated to revolutionize treatment paradigms, demonstrating promising compliance and market uptake driven by established infrastructure, suggesting a robust commercial opportunity in the near future.
Bears say
Tyra Biosciences Inc reported a significant net loss of $25.6 million, or ($0.43) per share, which aligns closely with prior estimates but raises concerns about the company's financial sustainability. The company faces substantial risks regarding potential delays in the clinical development of its drug candidates TYRA-300 and TYRA-200, negative clinical outcomes, regulatory approvals, and competition from existing therapies that may hinder commercial success. Furthermore, the reported adverse effects associated with existing FGFR inhibitors underscore the challenges that Tyra's candidates must overcome to differentiate themselves in a competitive market.
This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares